Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study

• Published in: Cancers 2023-09, Vol.15 (18), p.4511
• Main Authors: Koinis, Filippos, Zafeiriou, Zafeiris, Messaritakis, Ippokratis, Katsaounis, Panagiotis, Koumarianou, Anna, Kontopodis, Emmanouil, Chantzara, Evangelia, Aidarinis, Chrissovalantis, Lazarou, Alexandros, Christodoulopoulos, George, Emmanouilides, Christos, Hatzidaki, Dora, Kallergi, Galatea, Georgoulias, Vassilis, Kotsakis, Athanasios
• Format: Article
• Language: English
• Subjects: Apoptosis; Biomarkers; Biopsy; Cancer; Cancer therapies; Castration; Chemotherapy; Clinical outcomes; Collaboration; Consent; Denosumab; Enrollments; Ethylenediaminetetraacetic acid; FDA approval; Immunofluorescence; Metastases; Metastasis; Multivariate analysis; Oncology, Experimental; Patients; Peripheral blood; Prostate cancer; Scintigraphy; Solid tumors; Tumor cells; Vimentin
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15184511

Rational: Circulating tumor cells (CTCs) appear to be a promising tool for predicting the clinical outcome and monitoring the response to treatment in patients with solid tumors. The current study assessed the clinical relevance of monitoring CTCs in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel. Patients and Methods: Patients with histologically confirmed mCRPC who were previously treated with a docetaxel-containing regimen and experienced disease progression were enrolled in this multicenter prospective study. CTC counts were enumerated using the CellSearch system at baseline (before cabazitaxel initiation), after one cabazitaxel cycle (post 1st cycle) and at disease progression (PD). Patients were stratified into predetermined CTC-positive and CTC-negative groups. The phenotypic characterization was performed using double immunofluorescence staining with anti-CKs and anti-Ki67, anti-M30 or anti-vimentin antibodies. Results: The median PFS and OS were 4.0 (range, 1.0–17.9) and 14.5 (range, 1.2–33.9) months, respectively. At baseline, 48 out of 57 (84.2%) patients had ≥1 CTCs/7.5 mL of peripheral blood (PB) and 37 (64.9%) had ≥5 CTCs/7.5 mL of PB. After one treatment cycle, 30 (75%) out of the 40 patients with available measurements had ≥1 detectable CTC/7.5 mL of PB and 24 (60%) ≥ 5CTCs/7.5 mL of PB; 12.5% of the patients with detectable CTCs at the baseline sample had no detectable CTCs after one treatment cycle. The detection of ≥5CTCs/7.5 mL of PB at baseline and post-cycle 1 was associated with shorter PFS and OS (p = 0.002), whereas a positive CTC status post-cycle 1 strongly correlated with poorer OS irrespective of the CTC cut-off used. Multivariate analysis revealed that the detection of non-apoptotic (CK+/M30−) CTCs at baseline is an independent predictor of shorter OS (p = 0.005). Conclusions: In patients with mCRPC treated with cabazitaxel, CTC counts both at baseline and after the first cycle retain their prognostic significance, implying that liquid biopsy monitoring might serve as a valuable tool for predicting treatment efficacy and survival outcomes.